Provider Helpline - Closed December 25, 2024, and January 1, 2025
A total of 577 patients were randomly assigned (1:1:1) to receive once-weekly dulaglutide (1.5 mg), once-weekly dulaglutide (0.75 mg), or daily insulin glargine as basal therapy, all in combination with insulin lispro, for 52 weeks
Peptides for Cardiovascular Research: Vasodilatory, Cardioprotective & Metabolic Compounds Ranked 7 compounds studied across vasodilatory, cardioprotective, and GLP-1 cardiac outcome research with 3 published CVOTs and Phase 3 mitochondrial trial data ranked by evidence depth
GLP-1, or Glucagon-Like Peptide-1, has gained attention in recent years for its role in weight management and insulin sensitivity, making it a valuable tool in managing PCOS symptoms
Abstract Diabetes is one of the main risk factors for the development of cognitive dysfunction
Frequently Asked Questions Why does the article say oral liquid formulations are taken on an empty stomach